Diagnosing and Treating Acute Hepatic Porphyria

Acute hepatic porphyria (AHP) is a rare condition with symptoms that are similar with other more common conditions (e.g., irritable bowel syndrome, fibromyalgia,
endometriosis). This causes some patients to go many years before the correct diagnosis is made. Irritable bowel syndrome (IBS) is a chronic and recurrent disorder of the GI tract usually accompanied by diarrhea, constipation or both. Fibromyalgia (FM) is a condition marked by muscle pain all over the body, sleep problems, and fatigue. Endometriosis is a painful condition in women where tissue like the lining of the uterus or womb grows on the outside of the organ.

Diagnosing Acute Hepatic Porphyria

The type of test that should be done depends on whether the person is having symptoms at the time. When a person is having symptoms from AHP, a spot urine test for porphobilinogen (PBG), a porphyrin, may be used. This test simply involves urinating in a specimen container, often a
small cup. The sample is then tested in the lab for PBG levels. If PBG levels are high, a healthcare provider can tell that a person has AHP.

Other tests that may be done include a urine test for aminolevulinic acid (ALA) as well as testing for total porphyrins in the urine, blood, or stool. If someone has severe kidney disease, a blood test for PBG may also be done. This is due to the kidney being unable to properly filter urine. As AHP is caused by a gene defect, genetic testing can also be used to diagnose the condition. Unlike the urine tests mentioned above, the genetic test can be done when a patient is not experiencing symptoms. Genetic testing is also helpful for diagnosing the condition in family members of those with known AHP. The genetic test looks for problems in 4 different genes and can diagnose the specific type of AHP that one may have (acute intermittent porphyria, variegate porphyria, hereditary coproporphyria, and ALAD-deficient porphyria).

Treating Acute Hepatic Porphyria

When someone with AHP is experiencing an acute attack, treatment with intravenous (IV) hemin in the hospital can help with symptoms. At that time, it is also important to try to identify what may have caused the attack (e.g., infection, medicine, diet changes) so that they can be avoided in the future.


A drug called Givosiran (Givalaari®) was approved by the U.S. Food and Drug Administration in 2019 for the treatment of adults with AHP. It is a medicine that is injected under the skin once a month. In clinical trials, patients on givosiran had fewer acute attacks from AHP when compared to those given a placebo. A placebo is a pill or treatment with no active ingredients. While taking givosiran, patients should have their liver and kidney tests monitored by their healthcare team. For patients with AHP who suffer from repeated severe attacks, do not respond to IV hemin or givosiran, or have a very poor quality of life, liver transplantation can be considered as a last resort.

Adapted from IFFGD’s publication #581 Understanding Acute Hepatic Porphyria by Christopher V. Almario, MD, MSHPM; Cedars-Sinai Medical Center, Karsh Division of Gastroenterology and Hepatology

Share this page
Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print
Topics of this article
Read More
Was this article helpful?

IFFGD is a nonprofit education and research organization. Our mission is to inform, assist, and support people affected by gastrointestinal disorders.

Our original content is authored specifically for IFFGD readers, in response to your questions and concerns.

If you found this article helpful, please consider supporting IFFGD with a small tax-deductible donation.

Related Information
Personal Stories
Skip to content